Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 8/20 | 0.65 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8421533 | 0.83 | PABPC1 (0.63) | HDAC1PABPC1MEN1KMT2ANPC1 | |
| SCHEMBL8083036 | 0.83 | HDAC1 (0.79) | HDAC1PABPC1HDAC4MEF2DMEN1 | |
| SCHEMBL10420281 | 0.82 | HDAC1 (0.73) | HDAC1 | |
| SCHEMBL8374731 | 0.81 | HDAC1 (0.62) | HDAC1PABPC1MEN1KMT2ALMNA | |
| SCHEMBL13159659 | 0.79 | HDAC1 (1.00) | HDAC1HDAC4MEF2D | |
| SCHEMBL8344769 | 0.79 | HDAC1 (1.00) | HDAC1HDAC4MEF2D | |
| SCHEMBL14462080 | 0.78 | HDAC1 (0.59) | HDAC1PABPC1HDAC4MEN1KMT2A | |
| SCHEMBL13159719 | 0.77 | HDAC1 (0.87) | HDAC1HDAC4MEF2D | |
| SCHEMBL8421283 | 0.77 | NPC1 (0.60) | HDAC1PABPC1HDAC4MEN1KMT2A | |
| SCHEMBL14264238 | 0.76 | MEN1 (0.60) | HDAC1HDAC4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7847122-B2 | Polymorphs of suberoylanilide hydroxamic acid | MERCK HDAC RESEARCH, LLC (US) | 2010-12-07 | — | — | US | disclosed |
| US-20080249179-A1 | Methods of treating cancer with HDAC inhibitors | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2008-10-09 | — | — | US | disclosed |
| US-20080228005-A1 | Polymorphs of suberoylanilide hydroxamic acid | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-09-18 | — | — | US | disclosed |
| US-20080227862-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. | 2008-09-18 | — | — | US | disclosed |
| US-7375137-B2 | Methods of treating cancer with HDAC inhibitors | MERCK HDAC RESEARCH, LLC (US) | 2008-05-20 | — | — | US | disclosed |
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | ATON PHARMA, INC. (US) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167103-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC1, HDAC4 | HDAC1 2/4885PABPC1 2559/4885HDAC4 3/4885 |
| US-20080249179-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC1 3/4885PABPC1 4409/4885HDAC4 4/4885 |
| US-20080228005-A1 | Polymorphs of suberoylanilide hydroxamic acid | HDAC1, HDAC4, HDAC5 | HDAC1 1/4885PABPC1 3027/4885HDAC4 2/4885 |
| US-20080227862-A1 | Methods of treating cancer with HDAC inhibitors | HDAC5, HDAC9, HDAC1 | HDAC1 3/4885PABPC1 4409/4885HDAC4 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.